Klarino man, I would couch that statement with the fact that it is still preliminary and limited results based on 5 patient, so still halfway up on this medical ladder.
It is good news though, having the "imaging agent" reach the lymph nodes is half the battle for this tech and certainly for this study.
Like I posted previously, even with bad news or the perception by others as bad news, it is an update and shareholders & investor will approve and show their approval.